Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Voyager Therapeutics (VYGR) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to 206.45%.

  • Voyager Therapeutics' EBITDA Margin fell 1717100.0% to 206.45% in Q3 2025 from the same period last year, while for Sep 2025 it was 403.92%, marking a year-over-year decrease of 4198500.0%. This contributed to the annual value of 81.7% for FY2024, which is 1347000.0% down from last year.
  • Voyager Therapeutics' EBITDA Margin amounted to 206.45% in Q3 2025, which was down 1717100.0% from 642.38% recorded in Q2 2025.
  • In the past 5 years, Voyager Therapeutics' EBITDA Margin ranged from a high of 1516.65% in Q4 2022 and a low of 3252.89% during Q1 2022
  • Moreover, its 5-year median value for EBITDA Margin was 332.84% (2021), whereas its average is 605.36%.
  • Per our database at Business Quant, Voyager Therapeutics' EBITDA Margin crashed by -29200500bps in 2022 and then surged by 33353800bps in 2023.
  • Quarter analysis of 5 years shows Voyager Therapeutics' EBITDA Margin stood at 20.3% in 2021, then surged by 7371bps to 1516.65% in 2022, then plummeted by -96bps to 62.84% in 2023, then tumbled by -984bps to 555.29% in 2024, then soared by 63bps to 206.45% in 2025.
  • Its EBITDA Margin stands at 206.45% for Q3 2025, versus 642.38% for Q2 2025 and 474.05% for Q1 2025.